{"id":"W2991659810","doi":"10.1016/j.jaad.2019.11.040","title":"Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials","year":2019,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":91,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Janssen Research and Development; LEO Pharma; Janssen Scientific Affairs; Janssen Pharmaceuticals; Celgene; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Biogen","keywords":"Medicine; Psoriasis; Adverse effect; Psoriasis Area and Severity Index; Clinical trial; Internal medicine; Placebo; Dermatology; Skin cancer; Surgery; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007026053,0.0006474396,0.001869373,0.000327838,0.0003265824,0.001142118,0.0005858199,0.00117482,0.002084206],"category_scores_gemma":[0.004564764,0.0002384664,0.002381931,0.0004354331,0.0005821727,0.001002216,0.0003682454,0.001960555,0.0002969291],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004252617,"about_ca_system_score_gemma":0.0005683936,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003807563,"about_ca_topic_score_gemma":0.0007983798,"domain_scores_codex":[0.9979246,0.00123112,0.0002116748,0.0001985346,0.0002243147,0.0002098161],"domain_scores_gemma":[0.9958683,0.001562253,0.001383914,0.00047005,0.0002674711,0.0004480281],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6345817,0.008708115,0.02575142,0.003598988,0.008981006,0.0001949542,0.000606871,0.00119747,0.01693222,0.0002930047,0.003371773,0.2957824],"study_design_scores_gemma":[0.4359249,0.348222,0.183657,0.0009433031,0.008453633,0.001233225,0.0003706248,0.001210293,0.006694011,0.000721148,0.0124494,0.0001204851],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9635834,0.03168271,0.0007384255,0.0004655051,0.0001164981,0.0005907268,0.0009363058,0.00006098916,0.001825503],"genre_scores_gemma":[0.9910307,0.005489483,0.0006438668,0.0005118115,0.0001256581,0.000407118,0.001075944,0.00001763049,0.0006978048],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007026053,"threshold_uncertainty_score":0.03715771,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03350037897020353,"score_gpt":0.3140369355287464,"score_spread":0.2805365565585429,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}